Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-876-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.39 billion
Profitability
Miscellaneous
Employees24,000
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) released its quarterly earnings data on Thursday, May, 9th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.08. The firm had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.09 billion. Syneos Health had a net margin of 0.42% and a return on equity of 9.55%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.55 earnings per share. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY19 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of $3.03-3.23 for the period, compared to the Thomson Reuters consensus estimate of $3.12. The company issued revenue guidance of $4.62-4.73 billion, compared to the consensus revenue estimate of $4.58 billion.Syneos Health also updated its FY 2019 guidance to $3.03-3.23 EPS.
What price target have analysts set for SYNH?
10 Wall Street analysts have issued 12 month price objectives for Syneos Health's stock. Their predictions range from $48.00 to $60.00. On average, they expect Syneos Health's stock price to reach $54.6250 in the next twelve months. This suggests a possible upside of 31.8% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
Media coverage about SYNH stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Syneos Health earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of Syneos Health own?
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair Macdonald, CEO & Director (Age 49)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
- Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
- Mr. Michael Adam Bell, Consultant (Age 63)
- Mr. Robert Parks, Exec. VP & Chief Accounting Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.06%), Wellington Management Group LLP (3.75%), ArrowMark Colorado Holdings LLC (2.26%), Viking Global Investors LP (2.14%), Goldman Sachs Group Inc. (1.87%) and Principal Financial Group Inc. (1.41%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which major investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, ArrowMark Colorado Holdings LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN, Dimensional Fund Advisors LP, Marshall Wace North America L.P., Marshall Wace LLP and Retirement Systems of Alabama. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health.
Which major investors are buying Syneos Health stock?
SYNH stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Rubric Capital Management LP, Rothschild & Co. Asset Management US Inc., Voya Investment Management LLC, Boston Partners, Pictet Asset Management Ltd., ClariVest Asset Management LLC and Geode Capital Management LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $41.43.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $4.30 billion and generates $4.39 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.
What is Syneos Health's official website?
How can I contact Syneos Health?
Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
